- Report
- August 2025
- 193 Pages
Global
From €3173EUR$3,545USD£2,772GBP
€3526EUR$3,939USD£3,080GBP
- Report
- August 2025
- 184 Pages
Global
From €3173EUR$3,545USD£2,772GBP
€3526EUR$3,939USD£3,080GBP
- Report
- August 2025
- 185 Pages
Global
From €3173EUR$3,545USD£2,772GBP
€3526EUR$3,939USD£3,080GBP
- Report
- August 2025
- 195 Pages
Global
From €3173EUR$3,545USD£2,772GBP
€3526EUR$3,939USD£3,080GBP
- Report
- April 2026
- 180 Pages
Global
From €5237EUR$5,850USD£4,574GBP
- Report
- April 2026
- 282 Pages
Global
From €5237EUR$5,850USD£4,574GBP
- Report
- April 2026
- 390 Pages
Global
From €5237EUR$5,850USD£4,574GBP
- Report
- April 2026
- 249 Pages
Global
From €5237EUR$5,850USD£4,574GBP
- Report
- February 2026
- 250 Pages
Global
From €4019EUR$4,490USD£3,511GBP
- Report
- February 2026
- 250 Pages
Global
From €4019EUR$4,490USD£3,511GBP
- Report
- February 2026
- 250 Pages
Global
From €4019EUR$4,490USD£3,511GBP
- Report
- February 2026
- 250 Pages
Global
From €4019EUR$4,490USD£3,511GBP
- Report
- February 2026
- 250 Pages
Global
From €4019EUR$4,490USD£3,511GBP
- Report
- February 2026
- 250 Pages
Global
From €4019EUR$4,490USD£3,511GBP
- Report
- April 2026
- 286 Pages
Global
From €5237EUR$5,850USD£4,574GBP
- Report
- June 2020
- 753 Pages
Global
From €2954EUR$3,300USD£2,580GBP
- Report
- April 2023
- 137 Pages
Global
From €6713EUR$7,500USD£5,864GBP
- Report
- March 2025
- 185 Pages
Global
From €4028EUR$4,500USD£3,519GBP
- Clinical Trials
- April 2025
- 280 Pages
Global
From €2685EUR$3,000USD£2,346GBP
- Clinical Trials
- April 2025
- 85 Pages
Global
From €1790EUR$2,000USD£1,564GBP

Pazopanib is an oncology drug used to treat certain types of cancer. It is a tyrosine kinase inhibitor, meaning it works by blocking the action of certain enzymes that are involved in the growth and spread of cancer cells. Pazopanib is used to treat advanced renal cell carcinoma, a type of kidney cancer, and advanced soft tissue sarcoma, a type of cancer that affects the connective tissues. It is also used to treat other types of cancer, such as ovarian cancer and thyroid cancer.
Pazopanib is available in tablet form and is taken orally. It is usually taken once daily, with or without food. Common side effects of pazopanib include nausea, vomiting, diarrhea, fatigue, and hair loss.
Some companies in the pazopanib market include GlaxoSmithKline, Novartis, and Pfizer. Show Less Read more